KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Receivables: 2009-2025

Historic Change in Receivables for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to -$48.7 million.

  • Biomarin Pharmaceutical's Change in Receivables fell 165.54% to -$48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year decrease of 81.57%. This contributed to the annual value of $57.9 million for FY2024, which is 69.59% down from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Change in Receivables is -$48.7 million, which was down 149.47% from $98.5 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Change in Receivables' 5-year high stood at $138.8 million during Q1 2023, with a 5-year trough of -$72.5 million in Q4 2024.
  • Its 3-year average for Change in Receivables is $32.3 million, with a median of $52.7 million in 2024.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Change in Receivables slumped by 293.25% in 2021 and then surged by 46,462.30% in 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Receivables (Quarterly) stood at -$61,000 in 2021, then soared by 46,462.30% to $28.3 million in 2022, then soared by 106.83% to $58.5 million in 2023, then tumbled by 224.02% to -$72.5 million in 2024, then crashed by 165.54% to -$48.7 million in 2025.
  • Its Change in Receivables stands at -$48.7 million for Q3 2025, versus $98.5 million for Q2 2025 and $57.6 million for Q1 2025.